Target in Sight: A Comprehensive Review of Hydroxychloroquine-Induced Bull’s Eye Maculopathy-Reference-Cited by-同舟云学术

Target in Sight: A Comprehensive Review of Hydroxychloroquine-Induced Bull’s Eye Maculopathy

Published:2024-02-23 Issue:3 Volume:12 Page:38-48
ISSN:2167-4868
Container-title:Current Ophthalmology Reports
language:en
Short-container-title:Curr Ophthalmol Rep

Author:

Snow Zachary,Seely Kai,Barrett Spencer,Pecha Joseph,Goldhardt Raquel

Funder

NIH - Center Core Grant

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40135-024-00321-6.pdf

Reference88 articles.

1. Gabourel JD. Effects of hydroxychloroquine on the growth of mammalian cells in vitro. J Pharmacol Exp Ther. 1963;141:122–30.

2. • Alarcón GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alén J, Bastian HM, Vilá LM, Reveille JD, LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(1168):1172. This study provides evidence for the indications of HCQ use.

3. Pons-Estel GJ, Alarcón GS, McGwin G, Danila MI, Zhang J, Bastian HM, Reveille JD, Vilá LM, Lumina Study Group. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61(830):839.

4. Willis R, Seif AM, McGwin G, et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: Data from LUMINA (LXXV), a multiethnic US cohort. Lupus. 2012;21:830–5.

5. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736–45.